Jazz Swings on Favorable Court Ruling
This article was originally published in The Pink Sheet Daily
An initial court ruling signals that the specialty pharma may be on the right track to staving off a generic version of narcolepsy drug Xyrem.
You may also be interested in...
Jazz will begin dispute resolution with FDA regarding the risk evaluation and mitigation strategy for its best-selling wakefulness drug.
The two biotech companies have teamed up to create a follow-on product to Jazz’s narcolepsy drug, a collaboration that could add to the patent-life of Xyrem and be financially beneficial for both companies.
The sale of an asset portfolio that includes Elsetrin for hot flashes could give Jazz the financial flexibility for another product acquisition.